Tanner Lloyd, Haynes Richard K, Wiesner Lubbe
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Centre of Excellence for Pharmaceutical Sciences, Faculty of Health Sciences, North-West University, Potchefstroom, South Africa.
Front Pharmacol. 2019 Feb 18;10:120. doi: 10.3389/fphar.2019.00120. eCollection 2019.
Tuberculosis (TB) is currently the leading cause of mortality due to an infectious disease, despite the existence of multiple effective first-line and second-line drugs. The current anti-TB regimen requires a prolonged treatment period of around 6 months and is only efficacious against drug-sensitive strains of (). With a rise in cases of multi-drug resistant and extensively drug resistant strains of , newer treatments comprising compounds with novel mechanisms of action are required. Although decoquinate (DQ) is inactive against , its derivatives are of interest to anti-TB drug discovery because of their potential to permeate the mycobacterial cell wall, -infected macrophages, and granulomatous lesions by passive diffusion. The compounds also display mechanisms of action which are unlike those of currently used quinolones, potentially displaying activity against new targets. Three such derivatives bearing an alkyl group at N-1 and an amide group at C-3 (RMB 041, -043, and -073) displayed potent activities against H37Rv (90% minimum inhibitory concentrations, MIC90 = 1.61, 4.18, and 1.88 μM, respectively) and high selectivity indices (10-25). In this study, we evaluated the drug-like properties ( microsomal stability, microsomal/plasma protein binding, kinetic solubility, lipophilicity, and passive permeability) and pharmacokinetic (PK) parameters of these compounds after intravenous and oral administration to male C57BL/6 mice. The compounds showed markedly improved kinetic solubilities compared to that of the parental DQ and were metabolically stable . The maximum concentrations reached after oral administration were 5.4 ± 0.40, 5.6 ± 1.40, and 2.0 ± 0.03 μM; elimination half-lives were 23.4 ± 2.50, 6.2 ± 0.80, and 11.6 ± 1.30 h; and bioavailabilities were 21.4 ± 1.0, 22.1 ± 2.2, and 5.9 ± 1.3 for RMB041, -043, and -073, respectively. These compounds therefore display promising drug-like properties, and their PK/toxicity profiles (including long half-lives both and ) support their potential as candidates for further investigation in animal models of infection.
尽管存在多种有效的一线和二线药物,但结核病(TB)目前仍是传染病致死的主要原因。当前的抗结核治疗方案需要约6个月的较长治疗期,且仅对药物敏感菌株有效。随着耐多药和广泛耐药菌株病例的增加,需要包含具有新作用机制化合物的新型治疗方法。尽管癸氧喹酯(DQ)对结核杆菌无活性,但其衍生物因其有可能通过被动扩散穿透分枝杆菌细胞壁、感染结核杆菌的巨噬细胞和肉芽肿病变,而在抗结核药物研发中受到关注。这些化合物还表现出与目前使用的喹诺酮类不同的作用机制,可能对新靶点具有活性。三种在N-1位带有烷基且在C-3位带有酰胺基的衍生物(RMB 041、-043和-073)对结核分枝杆菌H37Rv显示出强效活性(90%最小抑菌浓度,MIC90分别为1.61、4.18和1.88 μM)以及高选择性指数(10 - 25)。在本研究中,我们评估了这些化合物在静脉注射和口服给予雄性C57BL/6小鼠后的类药性质(微粒体稳定性、微粒体/血浆蛋白结合、动力学溶解度、亲脂性和被动通透性)和药代动力学(PK)参数。与母体DQ相比,这些化合物的动力学溶解度显著提高,且代谢稳定。口服给药后达到的最大浓度分别为5.4±0.40、5.6±1.40和2.0±0.03 μM;消除半衰期分别为23.4±2.50、6.2±0.80和11.6±1.30小时;RMB041、-043和-073的生物利用度分别为21.4±1.0、22.1±2.2和5.9±1.3。因此,这些化合物表现出有前景的类药性质,并且它们的PK/毒性特征(包括长半衰期)支持它们作为在结核感染动物模型中进一步研究的候选药物的潜力。